A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
暂无分享,去创建一个
M. Stölzel | Jeffrey Frankel | S. Herschorn | D. Castro-Diaz | A. Gousse | N. Martin | P. V. van Kerrebroeck | M. Espuña-Pons | J. Barkin | A. Gunther | D. Castro-Díaz | J. Frankel